TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an update.
OncoSil Medical Limited announced that its CEO, Nigel Lange, will present at the 2025 Bell Potter Healthcare Conference in Sydney, Australia. This presentation underscores OncoSil’s commitment to advancing its position in the medical device sector, particularly in the treatment of pancreatic cancer, and highlights the company’s ongoing efforts to expand its market presence and stakeholder engagement.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company specializing in Interventional Oncology. The company focuses on improving cancer treatment outcomes through the intratumoural placement of Phosphorous-32 Microparticles, particularly for unresectable locally advanced pancreatic cancer. OncoSil’s device allows for targeted radiation delivery, sparing surrounding organs, and has received CE Marking approval, enabling its use in over 30 countries, including the EU, UK, Turkey, and Israel.
Average Trading Volume: 23,209
Technical Sentiment Signal: Sell
Current Market Cap: A$21.46M
See more data about OSL stock on TipRanks’ Stock Analysis page.